Source link : https://newshealth.biz/health-news/mavacamten-poised-to-expand-to-pediatric-obstructive-hypertrophic-cardiomyopathy/
NEW ORLEANS — The benefit of mavacamten (Camzyos) held up in symptomatic adolescents with obstructive hypertrophic cardiomyopathy (HCM), the phase III SCOUT-HCM trial showed. Already available to adults, the cardiac myosin inhibitor led to reductions in left ventricular outflow tract (LVOT) obstruction, with a mean difference in change in Valsalva LVOT gradient of -48.0 mm […]
The post Mavacamten Poised to Expand to Pediatric Obstructive Hypertrophic Cardiomyopathy first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-30 16:52:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8